<noscript id="z2oot"></noscript>

    免费A级毛片无码免费视频120软件,日韩毛片无码永久免费看,A级毛片免费观看,毛片免费视频,免费A级毛片无码A∨免费软件_第1页
    Create profile
    EN



    MHRA approves first oral antiviral for the treatment of COVID-19
    Source: Writer:CODEX Date:2021-09-17 View: 1582

    The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency (MHRA) announced today.


    This follows a rigorous review of its safety, quality and effectiveness by the UK regulator and the government's independent expert scientific advisory body, the Commission on Human Medicines, making it the first oral antiviral for the treatment of COVID-19 to be approved.


    Developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), Lagevrio works by interfering with the virus' replication. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.


    Based on the clinical trial data, Lagevrio is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible following a positive COVID-19 test and within five days of symptoms onset

    Molnupiravir has been authorised for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.


    Health and Social Care Secretary Sajid Javid said:

    "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for COVID-19. This will be a gamechanger for the most vulnerable and the immunosuppressed, who will soon be able to receive the ground-breaking treatment.


    "The UK is leading the way to research, develop and roll out the most exciting, cutting-edge treatments, and my thanks goes to the expert teams at the MHRA and MSD for this triumph, as well as the Antivirals Taskforce who have procured the treatment.


    "We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible

    "This antiviral will be an excellent addition to our armory against COVID-19, and it remains vital everyone comes forward for their life-saving COVID-19 vaccine - particularly those eligible for a booster - to ensure as many people as possible are protected over the coming months."



    Following a rigorous review of the data by our expert scientists and clinicians, we are satisfied that Lagevrio (molnupiravir) is safe and effective for those at risk of developing severe COVID-19 disease and have granted its approval.

    Lagevrio is another therapeutic to add to our armory against COVID-19. It is also the world's first approved antiviral for this disease that can be taken by mouth rather than administered intravenously. This is important, because it means it can be administered outside of a hospital setting, before COVID-19 has progressed to a severe stage.

    With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data."

    Dr June Raine, MHRA Chief Executive


    Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines, said:

    "The Commission on Human Medicines and its COVID-19 Therapeutics Expert Working Group has independently reviewed the data and endorses the MHRA's regulatory approval of Lagevrio.


    "In clinical trials, Lagevrio was found to be effective in reducing the risk of hospitalization or death for at-risk non-hospitalized adults with mild to moderate COVID-19 by 50%.


    "Based on this and other data that has been carefully reviewed by the Commission and its expert group, it is clear Lagevrio is another safe and effective treatment to help us in our fight against COVID-19."


    Lagevrio is not intended to be used as a substitute for vaccination against COVID-19.

    The government and the NHS will confirm how this COVID-19 treatment will be deployed to patients in due course.


    MHRA approves first oral antiviral for the treatment of COVID-19
    Source: Writer:CODEX Date:2021-09-17 Views: 1582 次

    The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency (MHRA) announced today.


    This follows a rigorous review of its safety, quality and effectiveness by the UK regulator and the government's independent expert scientific advisory body, the Commission on Human Medicines, making it the first oral antiviral for the treatment of COVID-19 to be approved.


    Developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), Lagevrio works by interfering with the virus' replication. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.


    Based on the clinical trial data, Lagevrio is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible following a positive COVID-19 test and within five days of symptoms onset

    Molnupiravir has been authorised for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.


    Health and Social Care Secretary Sajid Javid said:

    "Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for COVID-19. This will be a gamechanger for the most vulnerable and the immunosuppressed, who will soon be able to receive the ground-breaking treatment.


    "The UK is leading the way to research, develop and roll out the most exciting, cutting-edge treatments, and my thanks goes to the expert teams at the MHRA and MSD for this triumph, as well as the Antivirals Taskforce who have procured the treatment.


    "We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible

    "This antiviral will be an excellent addition to our armory against COVID-19, and it remains vital everyone comes forward for their life-saving COVID-19 vaccine - particularly those eligible for a booster - to ensure as many people as possible are protected over the coming months."



    Following a rigorous review of the data by our expert scientists and clinicians, we are satisfied that Lagevrio (molnupiravir) is safe and effective for those at risk of developing severe COVID-19 disease and have granted its approval.

    Lagevrio is another therapeutic to add to our armory against COVID-19. It is also the world's first approved antiviral for this disease that can be taken by mouth rather than administered intravenously. This is important, because it means it can be administered outside of a hospital setting, before COVID-19 has progressed to a severe stage.

    With no compromises on quality, safety and effectiveness, the public can trust that the MHRA has conducted a robust and thorough assessment of the data."

    Dr June Raine, MHRA Chief Executive


    Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines, said:

    "The Commission on Human Medicines and its COVID-19 Therapeutics Expert Working Group has independently reviewed the data and endorses the MHRA's regulatory approval of Lagevrio.


    "In clinical trials, Lagevrio was found to be effective in reducing the risk of hospitalization or death for at-risk non-hospitalized adults with mild to moderate COVID-19 by 50%.


    "Based on this and other data that has been carefully reviewed by the Commission and its expert group, it is clear Lagevrio is another safe and effective treatment to help us in our fight against COVID-19."


    Lagevrio is not intended to be used as a substitute for vaccination against COVID-19.

    The government and the NHS will confirm how this COVID-19 treatment will be deployed to patients in due course.


    Our Advantages
    Sixteen years of translation experience in medical and intellectual property fields
    Sixteen years of translation experience in medical and intellectual property fields
    Since the establishment, CODEX has been deeply engaged in medical translation. Quality translation and services are the driving force for our sustainable development.
    Professional and Elite Team
    Professional and Elite Team
    The translation team consists of graduates returned from abroad, post-graduate students from the most prestigious universities, professional native-speaking translators and consultants in the medical industry.
    Authoritative Quality Certification
    Authoritative Quality Certification
    We provide services for many world-renowned pharmaceutical companies with ISO9001:2015 and ISO17100:2015 Quality Management System Certification.
    Strict Control Process
    Strict Control Process
    Codex has established a perfect translation quality assurance system and systematic operation process, strictly adopts the working procedure of  “firstly translation, secondly modification, thirdly proofreading and fourthly review”.
    Excellent Staff Quality
    Excellent Staff Quality
    Being strictly examined and selected, every one of us is characterized with a strong sense of responsibility and proficiency in medical translation , and we strictly follow the confidential system.
    Client Support
    Client Support
    “Pursue Excellence, Strive for Perfection”. Serve you with quality and confidentiality .
    Contact Us
    CODEX By Your Side

    Beijing CODEX Translation Co.,LTD

    400-136-8786

    We Are Here For You 24/7
    Who We Are
    As one of the few medical translation suppliers in China that have been certified by ISO17100: 2015, we have been providing life sciences translation services, localization services and intellectual property translation services since our founding 16 years ago.
    Open a membership
    Send a verification code
    Sign up
    Already have an account? Sign in here
    Use your account
    Use your message
    Login
    Do not have an account? Sign up here
    Send a verification code
    Login
    Do not have an account? Sign up here
    Scan QR code
    CODEX WeChat Public Platform
    WeChat
    CODEX customer service
    Contact Us
    400-136-8786
    E-mail
    Info@codex-trans.com
    蜜月av免费下载,在线免费看成人啪啪啪,美女约炮打炮影院在线,免费A级毛片无码免费视频120软件教师学生视频网站,...